Ardelyx (ARDX) Projected to Post Earnings on Monday

Ardelyx (NASDAQ:ARDX) will likely be posting its Q2 2025 quarterly earnings results after the market closes on Monday, August 4th. Analysts expect Ardelyx to post earnings of ($0.12) per share and revenue of $82.69 million for the quarter.

Ardelyx (NASDAQ:ARDX) last issued its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.07). Ardelyx had a negative return on equity of 34.45% and a negative net margin of 14.86%. The company had revenue of $74.11 million during the quarter, compared to analysts’ expectations of $79.40 million. During the same quarter in the previous year, the company earned ($0.11) EPS. The firm’s quarterly revenue was up 61.1% compared to the same quarter last year. On average, analysts expect Ardelyx to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Ardelyx Stock Up 2.1%

Shares of ARDX opened at $4.33 on Friday. Ardelyx has a 52 week low of $3.21 and a 52 week high of $7.18. The company has a quick ratio of 3.81, a current ratio of 4.12 and a debt-to-equity ratio of 1.04. The company has a market capitalization of $1.04 billion, a price-to-earnings ratio of -19.68 and a beta of 0.68. The stock’s 50-day moving average price is $4.05 and its 200-day moving average price is $4.64.

Insider Buying and Selling at Ardelyx

In other news, Director David M. Mott bought 200,000 shares of Ardelyx stock in a transaction on Monday, June 16th. The stock was acquired at an average price of $3.63 per share, with a total value of $726,000.00. Following the completion of the acquisition, the director directly owned 2,896,871 shares of the company’s stock, valued at $10,515,641.73. The trade was a 7.42% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Mike Kelliher sold 14,522 shares of the stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $4.08, for a total value of $59,249.76. Following the transaction, the insider directly owned 282,158 shares of the company’s stock, valued at $1,151,204.64. The trade was a 4.89% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have acquired 500,000 shares of company stock valued at $1,793,000 and have sold 83,477 shares valued at $340,586. 4.80% of the stock is owned by insiders.

Hedge Funds Weigh In On Ardelyx

A number of hedge funds have recently made changes to their positions in ARDX. Focus Partners Wealth acquired a new position in shares of Ardelyx during the first quarter valued at approximately $72,000. Strs Ohio purchased a new position in Ardelyx during the first quarter worth approximately $135,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Ardelyx by 2.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 159,061 shares of the biopharmaceutical company’s stock worth $781,000 after buying an additional 4,436 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in Ardelyx by 10.3% during the first quarter. Goldman Sachs Group Inc. now owns 2,378,738 shares of the biopharmaceutical company’s stock worth $11,680,000 after buying an additional 221,486 shares in the last quarter. Institutional investors and hedge funds own 58.92% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on ARDX shares. HC Wainwright started coverage on Ardelyx in a research report on Wednesday, June 18th. They set a “buy” rating and a $10.00 price target on the stock. Citigroup lowered their price target on Ardelyx from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday, May 2nd. Wall Street Zen downgraded Ardelyx from a “hold” rating to a “sell” rating in a research report on Monday, May 5th. Finally, Raymond James Financial downgraded Ardelyx from a “strong-buy” rating to an “outperform” rating and set a $11.00 price target on the stock. in a research report on Friday, May 2nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $10.89.

Ardelyx Company Profile

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.